Natural product therapy for KRAS-mutant lung cancer: Grifolin, an antitumor natural product from the mushroom Albatrellus confluens, decreases the expression of XPO1, increases the level of NFKBIA, inhibits NFKB transcriptional activity and suppresses the progression of KRAS-mutant lung cancer via up regulation of its target gene, 15/November/2016, 9.31 pm

Natural product therapy for Breast Cancer: Kukoamine A (KuA), a spermine alkaloid derived from Cortex lycii radicis and Lycium chinense among others, increases the levels of tumor suppressor p53, decreases the expression of metastasis promoter Snail1, inhibits the proliferation of tumor-initiating cells, suppresses epithelial-to-mesenchymal transition and the progression of metastasis, and supports tumor relapse-free survival in breast cancer patients, 15/November/2015, 1.04 pm
November 15, 2016
Natural product therapy for triple-negative breast tumors: Isoliquiritigenin, found in Licorice, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 15/November/2015, 10.02 pm
November 15, 2016
Show all

What they say: 

A recent study from the Department of Cell Biology, University of Texas Southwestern Medical Center, Texas 75390, USA shows that XPO1 can be pharmacologically targeted in KRAS-mutant lung cancer. This study was published in the 28 September 2016 issue of Nature by Prof Michael A.White, Kim, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for KRAS-mutant lung cancer: Grifolin, an antitumor natural product from the mushroom Albatrellus confluens,  decreases the expression of XPO1, increases the level of NFKBIA, inhibits NFKB transcriptional activity and suppresses the progression of KRAS-mutant lung cancer via up regulation of its target gene


Significance:

Given that: (1) 20-30% of people with lung cancer have mutations in k-ras gene; (2) out of 1.82 million people diagnosed with lung cancer in 2012, 1.56 million people died; (3) most of the k-ras mutation-containing lung tumors are not amenable to radiation therapy; (4) there are no effective anti-ras therapy available at present; (5) lung cancer is one of the most frequent cancer in men; (6) lung cancer is more common in developed countries than in developing countries; and (7) the global economic cost spent for lung cancer treatment is enormous, there is an urgent need to find: (a) a newer and effective treatment for K-ras mutated lung cancers; (b) a cheaper alternative to the existing expensive non-specific drugs; and (c) a Natural product-based side-effect-free drug.


What is known?

Prof. Michael A. White’s research team has recently shown that inhibition of XPO expression in lung cancer inhibits the progression of K-ras mutated lung cancer through down-regulation of NFKB transcriptional activity.


From Research findings to Therapeutic opportunity: 

On the foundation of this interesting finding, this study suggests a Natural product-based anti-cancer therapy for K-ras mutated human cancers. Grifolin, by increasing the expression of its target gene, it may decrease the expression of XPO1.

Figure 1  Figure 1 Grifolin increases the expression of anti-tumor cytokines, augment anti-tumor activity, and inhibit metastatic cancer progression via downregulation via PD-1

Figure 1  Grifolin suppresses progression of Kras-mutated human cancers via down regulation of XPO

Grifolin

Thereby, it may: (1) increase the levels of NFKBIA, (2) inhibit NFKB transcriptional activity; and (3) suppress the progression of KRAS-mutant lung cancer. Thus, by treating lung cancer patients with Grifolin, one may prevent the progression of Kras-mediated lung cancer.

Together, this study suggests that pharmacological formulations encompassing “Grifolin its analogues”  may be used to inhibit the progression of Kras-mediated lung cancer.


Idea Proposed/Formulated (with experimental evidence) by: 

Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or newbioideas.com 

Citation: Boominathan, L., Natural product therapy for KRAS-mutant lung cancer: Grifolin, an antitumor natural product from the mushroom Albatrellus confluens, decreases the expression of XPO1, increases the level of NFKBIA, inhibits NFKB transcriptional activity and suppresses the progression of KRAS-mutant lung cancer via up regulation of its target gene, 15/November/2016, 9.32 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


Undisclosed mechanistic information: How Grifolin decreases the expression of XPO1?

Amount: $200#

guaranteed-to-work1

Comments are closed.